49,267
edits
Difference between revisions of "Prostate-specific antigen"
Jump to navigation
Jump to search
Prostate-specific antigen (view source)
Revision as of 16:05, 21 September 2025
, 16:05, 21 September 2025→Free serum PSA/total PSA
(→A forumla for PSAD: +free PSA/total PSA) |
|||
| Line 58: | Line 58: | ||
====Free serum PSA/total PSA==== | ====Free serum PSA/total PSA==== | ||
:Also ''PSA free-to-total ratio'' (abbreviated ''FTR''<ref name=pmid39607059>{{cite journal |authors=Sii S, Papa N, Yiu TW, Tempo J, Qu L, Perera M, Thompson I, Ischia J, Fleshner N, Smith E, Ranasinghe W, Bolton D, Woon DT |title=Utility of PSA free-to-total ratio for clinically significant prostate cancer in men with a PSA level of <4 ng/mL |journal=BJU Int |volume=135 |issue=4 |pages=550–556 |date=April 2025 |pmid=39607059 |doi=10.1111/bju.16597 |url=}}</ref>) and ''PSA free/PSA ratio'' | :Also ''PSA free-to-total ratio'' (abbreviated ''FTR''<ref name=pmid39607059>{{cite journal |authors=Sii S, Papa N, Yiu TW, Tempo J, Qu L, Perera M, Thompson I, Ischia J, Fleshner N, Smith E, Ranasinghe W, Bolton D, Woon DT |title=Utility of PSA free-to-total ratio for clinically significant prostate cancer in men with a PSA level of <4 ng/mL |journal=BJU Int |volume=135 |issue=4 |pages=550–556 |date=April 2025 |pmid=39607059 |doi=10.1111/bju.16597 |url=}}</ref>) and ''PSA free/PSA ratio'' | ||
* High values of FTR have a lower risk of | * High values of FTR have a lower risk of prostate cancer. | ||
** Modelling based on a cohort 406 men showed that: FTR ≤0.15 ~46% had prostate cancer versus FTR ≥0.20 ~22% had prostate cancer.<ref name=pmid39607059> | ** Modelling based on a cohort 406 men showed that: FTR ≤0.15 ~46% had prostate cancer versus FTR ≥0.20 ~22% had prostate cancer.<ref name=pmid39607059/> | ||
===Phoenix definition of biochemical failure=== | ===Phoenix definition of biochemical failure=== | ||